Inhibitors of the Renal Outer Medullary Potassium channel
View Patent ↗This invention relates to compounds of Formula I having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
1. A compound having structural Formula I:
or a pharmaceutically acceptable salt thereof wherein:
—X—R—(CH 2 )n2- is
and where R
is
a is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 OCH 2 — or absent; wherein the —CH 2 — is optionally substituted with 1-2 of —F, and wherein the —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 OCH 2 — is optionally substituted with 1-3 of —F; and wherein a forms a bridge between two non-adjacent carbons;
R 5 is —H, —F with the proviso that —F is not attached to a carbon also bonded to nitrogen, —CH 3 , —CF 3 , —CHF 2 , —CHF 2 , or —CH 2 OH, or R 5 represents di-substitution on a single carbon with two of —F with the proviso that the two —F are not attached to a carbon also bonded to nitrogen, or two of —CH 3 ;
R 6 and R 7 are individually either —H, —C 1-3 alkyl optionally substituted with 1-3 of —F, or R 6 and R 7 can be taken together with the carbon atom to which they are attached to form C 4-3 cycloalkyl optionally substituted with 1-3 of —F;
R 8 is —H, —F, —CH 3 , —CF 3 , —CHF 2 , —CH 2 F, or —CH 2 OH, or phenyl optionally substituted with 1-3 of —F or —C 1-3 alkyl;
n1 and n2 can be individually either 0 or 1;
one of W 1 and W 2 is N and the other is CH;
R 1 and R 2 are each independently —H, —F, —Cl, —Br, cyclopropyl, —C 1-3 alkyl optionally substituted with 1-3 of —F, or —OC 1-3 alkyl optionally substituted with 1-3 of —F;
one of R 3a and R 3b is —CN, tetrazolyl, or —S(O) 2 C 1-3 alkyl and the other is —H, —F, —Cl, —Br, —S—CH 3 , —NH—CH 3 , —O-cyclopropyl, —C 1-3 alkyl optionally substituted with 1-3 of —F, or —OC 1-3 alkyl optionally substituted with 1-3 of —F;
one of R 4a and R 4b is —CN, tetrazolyl, or —S(O) 2 C 1-3 alkyl and the other is —H, —F, —Cl, —Br, —S—CH 3 , —NH—CH 3 , —O-cyclopropyl, —C 1-3 alkyl optionally substituted with 1-3 of —F, or —OC 1-3 alkyl optionally substituted with 1-3 of —F;
R a , R aa , R b and R bb are each independently —H, —F, —Cl, —C 1-3 alkyl optionally substituted with 1 to 3 of —F, or —OC 1-3 alkyl optionally substituted with 1 to 3 of —F;
R c and R d are each independently —H, —F, —Cl, —C 1-3 alkyl optionally substituted with 1 to 3 of —F, or —OC 1-3 alkyl optionally substituted with 1 to 3 of —F;
X is absent or C 1 alkyl having 2 substituents independently —H, or —C 1-3 alkyl optionally substituted with 1 to 3 of —F, wherein two —C 1-3 alkyl substituents can be taken together with the C 1 alkyl to which they are attached to form a —C 3-6 cycloalkyl; and
one of Y 1 or Y 2 is —CH(OH)—; and the other is —CH(OH)—; —S(O) 2 —; —S(O) 2 CH 2 —; —CH 2 — wherein —CH 2 — is optionally substituted with —C 1-3 alkyl optionally substituted with —OH, —OC 1-3 alkyl, or -1-3 of —F, or absent; provided that where Y 1 or Y 2 is —S(O) 2 — or —S(O) 2 CH 2 —, then the adjacent n1 or n2, respectively, is 0; and provided further that where Y 1 or Y 2 is —CH(OH)—, then the adjacent n1 or n2, respectively, is 1.
2. The compound of claim 1 wherein R is:
or a pharmaceutically acceptable salts thereof.
3. The compound of claim 1 wherein R is:
or a pharmaceutically acceptable salts thereof.
4. The compound of claim 1 wherein:
or a pharmaceutically acceptable salts thereof.
5. The compound of claim 1 wherein:
or a pharmaceutically acceptable salts thereof.
6. The compound of claim 1 wherein:
one of R 3a and R 3b is —CN or tetrazolyl and the other is —H, —F, —Cl, —Br, —C 1-3 alkyl optionally substituted with 1-3 of —F, or —OC 1-3 alkyl optionally substituted with 1-3 of —F; and/or
one of R 4a and R 4b is —CN or tetrazolyl and the other is —H, —F, —Cl, —Br, —C 1-3 alkyl optionally substituted with 1-3 of —F, or —OC 1-3 alkyl optionally substituted with 1-3 of —F;
or a pharmaceutically acceptable salts thereof.
7. The compound of claim 1 wherein a is —CH 2 — or absent or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 wherein a is absent or a pharmaceutically acceptable salt thereof.
9. compound selected from:
5-{(1R)-1-Hydroxy-2-[2-({[(2R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]amino}methyl)piperidin-1-yl]ethyl}-4-methyl-2-benzofuran-1(3H)-one;
5-{(1R)-1-Hydroxy-2-[2-({[2-hydroxy-1-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]amino}methyl)piperidin-1-yl]ethyl}-4-methyl-2-benzofuran-1(3H)-one;
5-{(1R)-1-Hydroxy-2-[3-({[(2R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]amino}methyl)-3-methylpiperidin-1-yl]ethyl}-4-methyl-2-benzofuran-1(3H)-one;
6-{1-Hydroxy-2-[({1-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]piperidin-2-yl}methyl)amino]ethyl}pyridine-3-carbonitrile;
5-{(1R)-1-Hydroxy-2-[(1S,4S)-6-{[(2R)-2-hydroxy-2-(4-methyl-1-oxo-1,3-dihydro-2-benzofuran-5-yl)ethyl]amino}-2-azabicyclo[2.2.1]hept-2-yl]ethyl}-4-methyl-2-benzofuran-1(3H)-one;
6-(3-((R)-2-Hydroxy-2-(4-methyl-1-oxo-1,3-dihydroisobenzofuran-5-yl)ethylamino)piperidin-1-yl)nicotinonitrile;
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprised of a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.